Stock Events

Stock Events

Sareum 

€0.14
0
+€0.01+6.98% Friday 16:47

Statistics

Day High
0.17
Day Low
0.14
52W High
0.29
52W Low
0.12
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MarExpected
Q4 2025
-0.01
0.32
0.65
0.99
Expected EPS
N/A
Actual EPS
-0.01403486016

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RYH0.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN.LSE
Mkt Cap237.53B
GSK
GSK.LSE
Mkt Cap85.7B
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb, with a strong portfolio in oncology, cardiovascular, and immunoscience, competes in the development of novel therapies, similar to Sareum's research focus.
Merck
MRK
Mkt Cap298.84B
Merck & Co., known for its innovative cancer treatments and vaccines, competes with Sareum in the oncology and immunotherapy sectors.
Pfizer
PFE
Mkt Cap161.09B
Pfizer, with a broad range of therapeutic areas including oncology, competes with Sareum in the development and commercialization of cancer treatments.
Roche
RHHBY
Mkt Cap321.08B
Roche Holding AG, specializing in biotechnology products for oncology, immunology, and infectious diseases, competes with Sareum in the cancer research and development space.
Novartis
NVS
Mkt Cap297.32B
Novartis AG, focusing on innovative medicines in areas like oncology and immunology, competes with Sareum in the development of new treatments for cancer and autoimmune diseases.
AMGEN
AMGN
Mkt Cap187.56B
Amgen, with a focus on human therapeutics in areas including oncology/hematology, competes with Sareum in the development of cancer and autoimmune disease treatments.
Lilly(Eli) &
LLY
Mkt Cap837.36B
Eli Lilly and Company, focusing on cancer, endocrinology, and immunology, competes with Sareum in the development of therapies for various diseases, including cancer.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals, known for its innovative biotechnology products in oncology and immunology, competes with Sareum in the research and development of treatments for cancer and autoimmune diseases.

About

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Chk 1 inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms. The company has strategic collaboration with Receptor.AI launched in August 2025 to accelerate discovery and optimisation of BBB-permeable TYK2/JAK1 inhibitors; and completion of initial stage expected Q4 2025. Sareum Holdings plc was formerly known as Keepfast plc and changed its name to Sareum Holdings plc in July 2004. The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom.
Show more...
CEO
Dr. Stephen Barry Parker DPhil, M.B.A., Ph.D.
Employees
5
Country
United Kingdom
ISIN
GB00BMC3RJ87

Listings

STU
DE
RYH0.STU
LSE
GB
SAR.LSE
F
DE
RYH0.F

0 Comments

Share your thoughts

FAQ

What is Sareum stock price today?▼
The current price of RYH0.STU is €0.14 EUR — it has increased by +6.98% in the past 24 hours. Watch Sareum stock price performance more closely on the chart.
What is Sareum stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Sareum stocks are traded under the ticker RYH0.STU.
Is Sareum stock price growing?▼
RYH0.STU stock has risen by +6.98% compared to the previous week, the month change is a +6.15% rise, over the last year Sareum has showed a -22.03% decrease.
When is the next Sareum earnings date?▼
Sareum is going to release the next earnings report on October 26, 2026.
What were Sareum earnings last quarter?▼
RYH0.STU earnings for the last quarter are -0.01 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Sareum have?▼
As of April 11, 2026, the company has 5 employees.
In which sector is Sareum located?▼
Sareum operates in the Health & Wellness sector.
When did Sareum complete a stock split?▼
Sareum has not had any recent stock splits.
Where is Sareum headquartered?▼
Sareum is headquartered in Cambridge, United Kingdom.